Company: SYRA
Filing Date: 2025-02-05
Form Type: S-3/A
Source: 0001493152-25-005032
Chunk: 42

Company: Syra Health Corp
Filing Date: 2025-02-05
Form: S-3/A
Chunk 42
---
 and neither we, nor any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.

<div align='center'>PLAN OF DISTRIBUTION</div>

We may sell the securities being offered hereby in one or more of the following ways from time to time:

| ● | through                               
 agents to the public or to investors; |

| ● | to                                                     
 underwriters for resale to the public or to investors; |

| ● | negotiated    
 transactions; |

| ● | block   
 trades; |

| ● | directly         
 to investors; or |

| ● | through                                        
 a combination of any of these methods of sale. |

| -27- |

As set forth in more detail below, the securities may be distributed from time to time in one or more transactions:

| ● | at                                             
 a fixed price or prices, which may be changed; |

| ● | at                                            
 market prices prevailing at the time of sale; |

| ● | at                                                  
 prices related to such prevailing market prices; or |

| ● | at                 
 negotiated prices. |

We will set forth in a prospectus supplement the terms of that particular offering of securities, including:

| ● | the                                          
 name or names of any agents or underwriters; |

| ● | the                                                                                            
 purchase price of the securities being offered and the proceeds we will receive from the sale; |

| ● | any                                                                                         
 over-allotment options under which underwriters may purchase additional securities from us; |

| ● | any                                                                                                       
 agency fees or underwriting discounts and other items constituting agents’ or underwriters’ compensation; |

| ● | any                            
 initial public offering price; |

| ● | any                                                                    
 discounts or concessions allowed or re-allowed or paid to dealers; and |

| ● | any                                                                     
 securities exchanges or markets on which such securities may be listed. |

Only underwriters named in an applicable prospectus supplement are underwriters of the securities offered by that prospectus supplement.

If underwriters are used in an offering, we will execute an underwriting agreement with such underwriters and will specify the name of each underwriter and the terms of the transaction (including any underwriting discounts and other terms constituting compensation of the underwriters and any dealers) in a prospectus supplement. The securities may be offered to the public either through underwriting syndicates represented by managing underwriters or directly by one or more investment banking firms or others, as designated. If an underwriting syndicate is used, the managing underwriter